Evidence map›Paper›PMID 28442584›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2017

Apparent CB

T W Grim, A J Morales, B F Thomas, J L Wiley, G W Endres, S S Negus, A H Lichtman

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Dissecting the role of CBEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2021
    Article
  9. Article
  10. Explication of CBDrug and alcohol dependence · 2020
    Article
  11. Article
  12. Article
  13. Molecular Mechanism and Cannabinoid Pharmacology.Handbook of experimental pharmacology · 2020
    Article
  14. Probing the CBMolecular pharmacology · 2019
    Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

T W GrimDepartment of Pharmacology, Virginia Commonwealth University, Richmond, Virginia (T.W.G., A.J.M., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (B.F.T., J.L.W.); and PinPoint Testing, LLC, AR (G.W.E.) tgrim@scripps.edu.
A J MoralesDepartment of Pharmacology, Virginia Commonwealth University, Richmond, Virginia (T.W.G., A.J.M., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (B.F.T., J.L.W.); and PinPoint Testing, LLC, AR (G.W.E.).
B F ThomasDepartment of Pharmacology, Virginia Commonwealth University, Richmond, Virginia (T.W.G., A.J.M., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (B.F.T., J.L.W.); and PinPoint Testing, LLC, AR (G.W.E.).
J L WileyDepartment of Pharmacology, Virginia Commonwealth University, Richmond, Virginia (T.W.G., A.J.M., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (B.F.T., J.L.W.); and PinPoint Testing, LLC, AR (G.W.E.).
G W EndresDepartment of Pharmacology, Virginia Commonwealth University, Richmond, Virginia (T.W.G., A.J.M., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (B.F.T., J.L.W.); and PinPoint Testing, LLC, AR (G.W.E.).
S S NegusDepartment of Pharmacology, Virginia Commonwealth University, Richmond, Virginia (T.W.G., A.J.M., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (B.F.T., J.L.W.); and PinPoint Testing, LLC, AR (G.W.E.).
A H LichtmanDepartment of Pharmacology, Virginia Commonwealth University, Richmond, Virginia (T.W.G., A.J.M., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (B.F.T., J.L.W.); and PinPoint Testing, LLC, AR (G.W.E.).
Virginia Commonwealth University · USCenter Point · USRTI International · US

Funding

TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI YAN ZHANG · 2014 to 2026
$13.8M
THC RECEPTORSR01DA003672 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI WILEY, JENNY L. · 1985 to 2018
$4.9M
Investigation of Synthetic Cannabinoid Exposures and Pharmacological ConsequencesR01DA040460 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI RANGAN MAITRA, Yanan Zhang · 2016 to 2026
$4.5M
Endocannabinoid modulation of pain-depressed behaviorR01DA030404 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S, SIM-SELLEY, LAURA J · 2011 to 2020
$3.7M
CB1 Allosteric Modulators: Molecular, Cellular and In Vivo PharmacologyR01DA039942 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI KINSEY, STEVEN G., LICHTMAN, ARON H · 2016 to 2020
$2.6M
NIDA NIH HHS P30 DA033934NIDA NIH HHS R01 DA003672NIDA NIH HHS R01 DA030404NIDA NIH HHS R01 DA039942NIDA NIH HHS R01 DA040460NIDA NIH HHS T32 DA007027
6 · The paper itself

Abstract

Synthetic cannabinoids (SCs) represent an emerging class of abused drugs associated with psychiatric complications and other substantial health risks. These ligands are largely sold over the internet for human consumption, presumably because of their high cannabinoid 1 receptor (CB

Indexed as

AnimalsCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsCannabinoidsDose-Response Relationship, DrugDronabinolDrug CombinationsFemaleMaleMiceMice, Inbred C57BLMice, TransgenicPiperidinesPyrazolesReceptor, Cannabinoid, CB1RimonabantCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsCannabinoidsDronabinolDrug CombinationsPiperidinesPyrazolesReceptor, Cannabinoid, CB1Rimonabant

Identifiers

PMID28442584
PMCPMC5478909
OpenAlexW2610040344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.